<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04228354</url>
  </required_header>
  <id_info>
    <org_study_id>NN9536-4649</org_study_id>
    <secondary_id>U1111-1241-6257</secondary_id>
    <secondary_id>2019-004020-37</secondary_id>
    <nct_id>NCT04228354</nct_id>
  </id_info>
  <brief_title>A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide</brief_title>
  <official_title>A Trial to Demonstrate Bioequivalence Between Semaglutide Drug Product Concentrations 0.68 mg/mL and 1.0 mg/mL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will look at how two different versions of semaglutide reach and stay in the blood
      after injection. The study aims to show similar levels of semaglutide in the blood when using
      the different versions. Participants will get both versions of semaglutide. The order in
      which participants receive the versions is decided by chance. Participants will get the
      medicines as an injection under the skin of the belly with the use of a pen-injector. The
      study will last for about 11 to 17 weeks. Participants will have 27 visits with the study
      doctor. At 2 visits, participants will stay in the clinic for 4 days and 3 nights.
      Participants may have to stop the study if the study doctor thinks that there are risks for
      their health. Women cannot take part if pregnant, breast-feeding or planning to become
      pregnant during the study period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 29, 2020</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Sponsor staff involved in the clinical trial is masked according to company standard procedures</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the semaglutide plasma concentration curve from 0 to tz</measure>
    <time_frame>0-840 hours</time_frame>
    <description>h*nmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum semaglutide plasma concentration</measure>
    <time_frame>0-840 hours</time_frame>
    <description>nmol/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the semaglutide plasma concentration curve</measure>
    <time_frame>0-840 hours</time_frame>
    <description>h*nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax for semaglutide</measure>
    <time_frame>0-840 hours</time_frame>
    <description>h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life</measure>
    <time_frame>0-840 hours</time_frame>
    <description>h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total apparent clearance of semaglutide</measure>
    <time_frame>0-840 hours</time_frame>
    <description>L/h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution of semaglutide</measure>
    <time_frame>0-840 hours</time_frame>
    <description>L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Semaglutide 0.68 mg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Semaglutide administered with the PDS290 pen-injector</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Semaglutide 1.0 mg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Semaglutide administered with the PDS290 pen-injector</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide</intervention_name>
    <description>Two doses of semaglutide given by subcutaneous (s.c., under the skin) injection with different drug product concentration and separated by 6 to 8 weeks</description>
    <arm_group_label>Semaglutide 0.68 mg/mL</arm_group_label>
    <arm_group_label>Semaglutide 1.0 mg/mL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 18-55 years (both inclusive) at the time of signing informed
             consent.

          -  Body mass index between 20.0 and 27.0 kg/m^2 (both inclusive).

        Exclusion Criteria:

          -  Female who is pregnant, breast-feeding or intends to become pregnant or is of
             child-bearing potential and not using highly effective contraceptive methods.

          -  Any disorder which in the investigator's opinion might jeopardise subject's safety,
             evaluation of results, or compliance with the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Reporting Anchor &amp; Disclosure (1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 13, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

